Research in proteomics has exploded in recent years with advances in mass spectrometry capabilities that have led to the characterization of numerous proteomes, including those from viruses, bacteria, and yeast. In comparison, analysis of the human proteome lags behind, partially due to the sheer number of proteins which must be studied, but also the complexity of networks and interactions these present. To specifically address the challenges of understanding the human proteome, we have developed HaloTag technology for protein isolation, particularly strong for isolation of multiprotein complexes and allowing more efficient capture of weak or transient interactions and/or proteins in low abundance. HaloTag is a genetically encoded protein fusion tag, designed for covalent, specific, and rapid immobilization or labelling of proteins with various ligands. Leveraging these properties, numerous applications for mammalian cells were developed to characterize protein function and here we present methodologies including: protein pull-downs used for discovery of novel interactions or functional assays, and cellular localization. We find significant advantages in the speed, specificity, and covalent capture of fusion proteins to surfaces for proteomic analysis as compared to other traditional non-covalent approaches. We demonstrate these and the broad utility of the technology using two important epigenetic proteins as examples, the human bromodomain protein BRD4, and histone deacetylase HDAC1. These examples demonstrate the power of this technology in enabling the discovery of novel interactions and characterizing cellular localization in eukaryotes, which will together further understanding of human functional proteomics.
Introduction
Understanding of cellular function, response to stimuli, and changes in development and/or disease states is intricately tied to de-convolution of the proteome throughout these different dynamic states 1, 2 . Much has been done to understand the proteome of lower organisms, however, given the number of proteins and all possible interactions, this has been very challenging in addressing the human proteome 1, [3] [4] [5] [6] [7] . Advances in mass spectrometry have greatly enabled the ability to undertake these studies, and here we present an additional and significant advancement with the development of HaloTag technology for both efficient capture of protein complexes and functional characterization of human proteins from mammalian cells [8] [9] [10] . This technology has recently been shown in several studies to be a critical factor for discovery of important interactions, allowing for insight into novel protein function and understanding of disease [11] [12] [13] . The HaloTag protein fusion was initially developed to address several challenges of traditional affinity tags and antibodies as related to protein capture, purification, and labelling [8] [9] [10] . Within nearly all methods for protein capture and purification, there is a non-covalent interaction step which is used for enrichment of a particular protein . The properties developed for the HaloTag protein and its co-developed resin address well these concerns. In the protocol for complex pulldowns (Figure 1) , binding of complexes can be achieved in 15 min, both promoting complex capture and reducing levels of non-specific binding 8 . In addition, irreversibly binding allows for efficient capture of low abundance proteins and allows for the use of far fewer cells, again reducing background 8 . Once capture of complexes is established, the protocol includes mild wash conditions to maintain complex integrity. Elution of captured complexes can be performed by two methods and choosing which method is dictated by the goal of the downstream analysis. If the desire is to analyse or discover interacting proteins by Western blot or mass spectrometry, then it is recommended to elute complexes with denaturants such as SDS or urea (Figure 1 ). This is particularly advantageous for mass spectrometry as the protein originally fused to HaloTag, termed the bait protein, will remain behind bound to the resin and therefore will not dominate the population of peptides detected in the mass spectrometry. This also means however that the bait protein will likely not be visible in analysis by western blot, a significant difference as compared to other non-covalent affinity purifications or co-immunoprecipitations. If the goal is to purify a complex intact to be used for functional studies, elution can be performed using TEV (Tobacco Etch Virus) protease, which recognizes its cognate cleavage sequence encoded between the fusion protein and the bait protein (Figure 1) . These samples could also be analysed by mass spectrometry, but as later shown, they will contain a significant amount of bait protein that may prevent detection of lower abundance, specific interactors.
Here we present pulldown and imaging protocols applied to two important therapeutical proteins, the bromodomain protein BRD4 and a histone deacetylase, HDAC1 17 . We have shown with these examples, interaction with expected partners as determined by mass spectrometry, enzymatic activity after complex isolation for HDAC1, and proper cellular localization for both. Together, these results demonstrate the multifunctional nature and strength of the technology for characterization of eukaryotic protein interactions and function.
Protocol
Note: The following protocol can be used with any HaloTag fusion and in any cell line of choice stably or transiently transfected. For these examples, we will give protocols for transient transfection of HaloTag fusions in HEK293T or HeLa cells. For all experiments, we recommend use of the protein only control.
Fusion Protein Expression Test
1. Obtain fusion protein construct:
1. Obtain pre-made HaloTag fusion vector or construct using existing vectors. For more information about available constructs, please see Table of Specific Reagents. 2. If making any clone, it is recommended to sequence verify the DNA.
2. Testing expression of fusion protein and control:
1. For each sample, prepare 250 μl of 1X SDS Loading Dye buffer (60 mM Tris HCL pH6.8, 0.75 mM bromophenol blue, 12.5% glycerol, 100 mM dithiothreitol, 0.5% SDS). 2. For each fusion protein and control, plate 0.5 ml of HEK293T or HeLa cells in their appropriate media at a density of 2-4 x 10 5 cells/ml in a standard 24 well plate. 3. Incubate for 18-24 hr at 37 °C and 5% CO 2 , then transfect as recommended. 4. 24 hr post-transfection, add 0.5 μl of 5mM tetra-methyl rhodamine (TMR) ligand to the media of each well and gently mix plate. 5. Incubate transfected cells containing ligand for 15 min at 37 °C and 5% CO 2. 6. Aspirate off media containing ligand and wash each well of cells gently with 1 ml RT PBS. 7. Aspirate off PBS and perform a second wash with 1 ml RT PBS. 8. Remove PBS and add 200 µl of 1X SDS Loading dye buffer directly to cells. 9. Pipette lysate from plate into 1.5 ml eppendorf tube. 10. Boil lysate for 5 min at 95 °C. 11. Remove 5-10 μl of the reaction and load onto SDS-PAGE gel. 12. Use a fluorescent detection scanner (TMR Excitation: 555 nm, Emission: 585 nm) to detect bands. Use fluorescent protein markers as standards. 13. If a fluorescent detection scanner is unavailable, perform western blots using antibodies against either the bait protein or protein fusion tag to detect expression of the fusion protein.
Protein Pulldowns Representative Results
When working with any new fusion protein, it is important to first test for expression of that protein after transfection and also validate that a protein of the proper molecular weight is being produced. As HaloTag fusion proteins can be fluorescently and covalently labelled with permeable or depending upon localization, impermeable ligands, it is possible to quickly determine expression by applying cellular lysates to denaturing gel electrophoresis followed by scanning on a fluorimager. Using the protocol described in Section 1.2, expression of Halo-BRD4 (189 kD) and the HaloTag alone control (Ctrl) is observed (34 kD, Figure 2A ). As mentioned in the protocol, the expression of fusion proteins can also be detected using traditional Western blots with anti-HaloTag antibodies, or if they are available, antibodies to the bait protein. If possible, it is recommended to use the fluorescent ligand instead as it is more specific, faster, and easier than antibody detection, and also quantitative 10 .
After expression of the proper full-length fusion protein is verified, protein pulldowns can be performed. Shown in Figure 2B are the silver stained gels of biological replicates of Halo-BRD4 and Ctrl pulldowns eluted by SDS (Protocol Section 2.4) which demonstrate high reproducibility. The silver stain gels show a significant number of proteins are found to interact with the BRD4 protein and very low background in the control ( Figure  2B ). As mentioned in the Introduction, in this process of elution, the Halo-BRD4 will not be eluted from the resin as it remains covalently bound. Therefore, there is not a significant band at this molecular weight being detected in the silver stain ( Figure 2B ) or western blot (data not shown).
To determine if these proteins are specific to BRD4, liquid chromatography mass spectrometry (LC-MS/MS) was performed on the complex mixture obtained after SDS elution. Shown in Figure 2C are spectral counts and normalized spectral abundance factor (NSAF) values for known interactors of BRD4 [18] [19] [20] found in the Halo-BRD4 mass spectrometry analysis. The high abundance of components from pTEFb 18, 20 and also the BRD9 19 protein confirm specific capture of BRD4 complexes. As predicted by the silver stain gels (Figure 2B) , numerous other proteins were also identified as potential interactors of BRD4 that were not observed in the control (data not shown). As these are previously unknown, they need to be independently verified by other methodologies to confirm whether the protein is a true interactor, and if so, if it is directly or indirectly associated with BRD4.
Isolated complexes can also be studied for activity; it is recommend to elute complexes using TEV protease (Protocol Section 2.5) so that they maintain functionality. In Figure 3A , a silver stain gel of Halo-HDAC1 pulldown complexes released from the resin using TEV protease is shown. As TEV protease will cleave in a linker region between the protein fusion tag and its fusion partner, significant amounts of the bait protein, in this case HDAC1, are observed ( Figure 3A) . To determine if this fraction contained HDAC1 activity, eluted TEV samples were tested in a luminescent HDAC assay, HDAC-Glo
21
. As shown in Figure 3B , HDAC1 pulldown samples showed high levels of HDAC1 activity (Column 1), which was specifically inhibited by a known HDAC inhibitor, SAHA 22 (Column 2). As controls to further demonstrate specificity, no HDAC inhibition was observed with a related sirtuin family inhibitor, EX-527 22 (Column 3) and no signal was detected using buffer alone without the
HDAC1 pulldown sample added (Column 4).
A significant component of functional proteomics and understanding complexes, is also understanding protein localization and/or trafficking. As these same fusion constructs can be fluorescently labelled inside cells, we monitored their localization using confocal imaging. Following the protocol in Section 3, HeLa cells transiently transfected with Halo-BRD4 ( Figure 4A ) and Halo-HDAC1 ( Figure 4B ) were fluorescently labelled with the TMR ligand and imaged. As shown in Figures 4A and 4B , both localized to the nucleus as expected 
Discussion
Presented here are two fusion proteins, Halo-BRD4 and Halo-HDAC1, characterized in eukaryotic mammalian cells for expression, protein complex isolation and activity, and cellular localization. In working through these various protocols, there are several important steps for the success of each experiment. As is the case with any fusion protein, expression level and placement of the tag itself can be critical for maintaining physiology. It is therefore important to consider that N-and/or C-terminal fusions will need to be designed if prior knowledge or work with another tag has not been demonstrated for the particular protein of choice. Regarding expression, if the level is too high, dilution of DNA can be performed during transfection or use of vectors with weaker promoters are possible to achieve the level that is appropriate. Previous work has been performed showing efficient isolation of macromolecular complexes at endogenous levels of expression 8 , enabling work at very low levels of expression. If possible, cellular localization studies would also be able to provide insight as to the optimal tag placement position as well as relative expression level needed for proper physiology.
Once the fusion proteins are ready for pulldown experiments, to obtain maximum success with the protocol it is very important to follow the recommended time frames in the lysis, binding, and washing sections, as one of the biggest advantages is the speed of the complex isolation process. If any of these steps are lengthened in time, such as is required for an antibody-based capture method, there is a risk of complex disassociation or increased non-specific binding 8 . Similarly if the times are shortened during cellular lysis or binding, cells may not be completely lysed or efficiently captured respectively. If the number of washes is decreased or good mixing of the resin does not occur during the binding or washes, then background levels of non-specific proteins will be increased. Also, the means of lysis is very important as related to the binding efficiency to the resin. Attempts to sonicate the samples, remove the recommended detergent, add SDS or other strong detergent, and/or include the protease inhibitor AEBSF will result in reduced or loss of binding of fusion proteins and their complexes to the resin.
Existing methods for complex isolation from mammalian cells and human proteomic analysis struggle with the challenge of reducing background in analysis by mass spectrometry 16 . This has been so significant that a repository of contaminating proteins has been created by numerous mass spectrometry groups 16 . Background in mass spectrometry pulldown samples can be defined as anything which prevents identification of true interactors of the bait protein. As such, background can arise from contaminating non-specific proteins or also large concentrations of bait protein or antibodies used to precipitate bait proteins. Significant work was done in optimizing both the pulldown protocol presented here as well as the resin to minimize the level of the non-specific contaminating proteins in the pulldown process. This is evident in the silver stain gels and mass spectrometry analysis of the control (Figure 2) . To address the high levels of bait protein or antibodies that can be equally detrimental as contaminants and with which other methodologies struggle, the pulldown with SDS elution is recommended (Protocol Section 2.4). Due to the covalent attachment to the resin, this process will leave the majority of the starting fusion protein covalently attached to the resin. A small percentage of bait is observed in the mass spectrometry analysis, which is believed to occur through hydrolysis, but it does not present a problem for detection of other weaker or transient interactions 8 .
As mentioned in the introduction, significant advances in proteomics have been enabled by significant advances in mass spectrometry 1, 7 . Therefore, it is important to highlight important parameters of the choice of mass spectrometry analysis to deconvolute the mixture of proteins obtained in the pulldowns. Instrumentation must be robust and capable of routinely and efficiently analysing samples containing a small amount of protein, often less than <1 µg. Nanoscale chromatography involving 50-75 µm internal diameter HPLC columns with flow rates in the 100-300 nl/min range is typically employed for compatibility with the small sample sizes and to maximize the sensitivity of the mass spectrometer. To maximize the information acquired in a single analysis state of the art mass spectrometers capable of acquiring high resolution mass spectra on a time scale compatible with aforementioned nanoscale separations, ≥10 Hz, are typically employed. These instruments have attomolar levels of sensitivity and can routinely acquire data with sub ppm precursor and product ion mass error tolerances. These performance characteristics serve to increase the yield of the number of identified proteins and the confidence associated with those identifications.
With these data we demonstrate physiological cellular localization, proper protein:protein interactions along with potential for discovery of novel interactions, and isolation of active complexes all using a single construct. Indeed alternative technologies can be used for each of these different aspects, but likely not for all 23, 24 . With the HaloTag technology, a multifunctional approach can be used, advancing proteomics studies and obtaining a more complete understanding of protein function in mammalian cells.
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